While ANXA1 is an important player in SCLC’s biology, due to tumor cell heterogeneity and the adaptability of this particularly malignant cancer, its intracellular signaling is probably highly redundant and sprawling, which makes its targeting in future drug trials challenging. The gene discussed is ANXA1; the disease is small cell lung carcinoma.